Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GemVax Seeks Revival Of Pancreatic Cancer Indication On ASCO Phase III Data

Executive Summary

New Phase III pancreatic cancer results for GV1001, an immunotherapeutic peptide, were presented at ASCO, which GemVax hopes will revive the drug after its conditional approval in South Korea was canceled last year.

You may also be interested in...



GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.

Diversification, Tailored Services Seen Key For CDMOs

Korea's Samsung Biologics talked during the BIO Digital event about the key trends and new paradigms in the CDMO industry in the COVID-19 era, including expansion, diversification and personalization. Forward planning helped overcome pandemic-related challenges but logistics remains a major challenge.

Should Global Pharmas Focus More On Korean Partners?

PharmaVentures’ Adrian Dawkes talks about how COVID-19 will impact pharma deals going forward and how Korean firms in particular may be able to grab opportunities in the global arena. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC144507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel